Skip to main content
Clinical Trials/ACTRN12618000306213
ACTRN12618000306213
Completed
Phase 4

Investigating the impact of regular cardio selective beta blockers on recovery with beta agonists following methacholine bronchoconstriction challenge in Asthmatics

Waikato District Health Board, Respiratory Research Fund0 sites21 target enrollmentMarch 1, 2018

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Asthma
Sponsor
Waikato District Health Board, Respiratory Research Fund
Enrollment
21
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 1, 2018
End Date
April 9, 2019
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Waikato District Health Board, Respiratory Research Fund

Eligibility Criteria

Inclusion Criteria

  • Physician diagnosis of asthma
  • Airway hyper responsiveness. Demonstrated with post mannitol ( a 15 percent decrease in FEV1 at a cumulative mannitol dose PD15 \<635mg/ml)
  • Over 18 years of age

Exclusion Criteria

  • Pre spirometry FEV1 \< 60% predicted or \< 1\.5L
  • Dyspnoea at rest
  • Past history of hypotension (baseline BP \<100/60\)
  • ECG abnormalities that could interfere with the interpretation of the study:
  • HR\<60/min
  • Symptomatic hypotension
  • ECG findings of severe 1st degree, or 2nd \& 3rd degree heart block (defined as PR interval \> 0\.28s)
  • LBBB \& RBBB are NOT excluded.
  • Known adverse reaction to beta blockers or mannitol
  • On other drugs that commonly interact with beta blockers (amiodarone, verapramil, cimetidine, digoxin, phenytoin)

Outcomes

Primary Outcomes

Not specified

Similar Trials